DRD3 Gene — Dopamine Receptor D3 <table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">DRD3 Gene</th>
</tr>
<tr>
<td class="label">
Gene Symbol </td>
<td>DRD3</td>
</tr>
<tr>
<td class="label">
Full Name </td>
<td>Dopamine Receptor D3</td>
</tr>
<tr>
<td class="label">
Chromosomal Location </td>
<td>3q13.31</td>
</tr>
<tr>
<td class="label">
NCBI Gene ID </td>
<td>1818</td>
</tr>
<tr>
<td class="label">
Ensembl ID </td>
<td>ENSG00000151577</td>
</tr>
<tr>
<td class="label">
UniProt ID </td>
<td>P35462</td>
</tr>
<tr>
<td class="label">
OMIM ID </td>
<td>139251</td>
</tr>
<tr>
<td class="label">
Protein Class </td>
<td>G Protein-Coupled Receptor (Class A)</td>
</tr>
<tr>
<td class="label">
Species </td>
<td>Human</td>
</tr>
<tr>
<td class="label">
Associated Diseases </td>
<td>[Parkinson's Disease](/diseases/parkinsons-disease), Restless Leg Syndrome, Schizophrenia, Dyskinesias, Addiction</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Type</td>
</tr>
<tr>
<td class="label">Pramipexole</td>
<td>Agonist</td>
</tr>
<tr>
<td class="label">Ropinirole</td>
<td>Agonist</td>
</tr>
<tr>
<td class="label">Rotigotine</td>
<td>Agonist</td>
</tr>
<tr>
<td class="label">Cariprazine</td>
<td>Partial agonist</td>
</tr>
</table>
Introduction ...
DRD3 Gene — Dopamine Receptor D3 <table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">DRD3 Gene</th>
</tr>
<tr>
<td class="label">
Gene Symbol </td>
<td>DRD3</td>
</tr>
<tr>
<td class="label">
Full Name </td>
<td>Dopamine Receptor D3</td>
</tr>
<tr>
<td class="label">
Chromosomal Location </td>
<td>3q13.31</td>
</tr>
<tr>
<td class="label">
NCBI Gene ID </td>
<td>1818</td>
</tr>
<tr>
<td class="label">
Ensembl ID </td>
<td>ENSG00000151577</td>
</tr>
<tr>
<td class="label">
UniProt ID </td>
<td>P35462</td>
</tr>
<tr>
<td class="label">
OMIM ID </td>
<td>139251</td>
</tr>
<tr>
<td class="label">
Protein Class </td>
<td>G Protein-Coupled Receptor (Class A)</td>
</tr>
<tr>
<td class="label">
Species </td>
<td>Human</td>
</tr>
<tr>
<td class="label">
Associated Diseases </td>
<td>[Parkinson's Disease](/diseases/parkinsons-disease), Restless Leg Syndrome, Schizophrenia, Dyskinesias, Addiction</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Type</td>
</tr>
<tr>
<td class="label">Pramipexole</td>
<td>Agonist</td>
</tr>
<tr>
<td class="label">Ropinirole</td>
<td>Agonist</td>
</tr>
<tr>
<td class="label">Rotigotine</td>
<td>Agonist</td>
</tr>
<tr>
<td class="label">Cariprazine</td>
<td>Partial agonist</td>
</tr>
</table>
Introduction Drd3 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Mermaid diagram (expand to render)
The DRD3 gene encodes the dopamine D3 receptor (D3R), a Gi/o protein-coupled receptor that is predominantly expressed in the limbic system and plays critical roles in reward, motivation, and movement control. D3R is a major therapeutic target for Parkinson's disease, particularly in the context of levodopa-induced dyskinesias, and is implicated in addiction, schizophrenia, and restless leg syndrome. The D3 receptor exhibits approximately 10-fold higher affinity for dopamine compared to the D2 receptor, making it particularly sensitive to endogenous dopamine fluctuations.
Molecular Function The D3 receptor is a member of the D2-like dopamine receptor family (along with DRD2 and DRD4) and couples primarily to Gi/o proteins, leading to:
Inhibition of adenylyl cyclase : Reduces cAMP production, counteracting D1-like receptor effectsActivation of G protein-gated potassium channels (GIRK) : Causes hyperpolarization, reducing neuronal firingInhibition of voltage-gated calcium channels : Reduces neurotransmitter releaseModulation of MAPK/ERK signaling : Affects gene expression and neuronal plasticityβ-arrestin recruitment : Triggers downstream signaling cascadesKey characteristics:
Highest dopamine affinity among dopamine receptors (Kd ~ 0.9 nM)Preferential localization to limbic system regionsExists in both pre- and postsynaptic locations as autoreceptors and postsynaptic receptorsAlternative splicing produces multiple receptor isoformsExpression Pattern
Brain Distribution
Highest expression : Nucleus accumbens (shell > core), islands of Calleja, olfactory tubercleHigh expression : Striatum (patch compartment), ventral pallidumModerate expression : Substantia nigra (pars compacta), ventral tegmental area, [hippocampus](/brain-regions/hippocampus), amygdalaLow expression : Cerebral [cortex](/brain-regions/cortex), cerebellumPeripheral Expression
Kidney : High expression in renal tubulesImmune cells : Lymphocytes, monocytes express DRD3Cardiovascular : Low expression in heart and blood vesselsEndocrine : Pituitary gland expressionRole in Neurodegenerative Diseases
Parkinson's Disease D3R plays a complex and central role in PD pathophysiology and treatment:
Altered expression : Postmortem studies show increased D3R binding in the striatum of PD patients, particularly in early disease stagesLevodopa-induced dyskinesias (LID) : D3R is heavily implicated in the development of LID; D3R-deficient mice show reduced dyskinesiasTherapeutic targeting : D3R-selective agonists (e.g., pramipexole, ropinirole) are first-line PD treatments that may have disease-modifying potentialGenetic variants : DRD3 polymorphisms (Ser9Gly) affect PD risk, age of onset, and treatment responseD3R vs D2R selectivity : Agonists with higher D3:D2 selectivity may reduce dyskinesia riskRestless Leg Syndrome (RLS)
First-line treatments : D3R agonists (pramipexole, ropinirole, rotigotine) are FDA-approved for RLSPathophysiology : D3R dysfunction in the mesolimbic pathway contributes to RLS sensory-motor symptomsAugmentation risk : Long-term use may lead to augmentation (worsening symptoms)Schizophrenia
Negative symptoms : D3R antagonists may improve negative symptoms and cognitive deficitsAntipsychotic binding : Most antipsychotics have high D3R occupancy (e.g., clozapine, cariprazine)Gene associations : DRD3 polymorphisms linked to schizophrenia susceptibilityAddiction
Reward pathway : D3R in nucleus accumbens mediates reward conditioningDrug seeking : D3R antagonists reduce cocaine, alcohol, and nicotine seeking in preclinical modelsIndividual vulnerability : DRD3 variants influence addiction riskTherapeutic Implications
Current Therapeutics
Research Directions
D3R-selective agonists : Develop compounds with higher D3:D2 ratio to reduce dyskinesiasAllosteric modulators : Target allosteric sites for more selective modulationβ-arrestin biased agonists : Bias toward β-arrestin pathways may provide benefitsGene therapy : Viral vector delivery of D3R genes under investigationAnimal Models
DRD3 Knockout Mice
Enhanced baseline locomotor activity
Reduced cocaine self-administration and reinforcement
Altered reward processing and emotional behavior
Improved working memory performance
Reduced levodopa-induced dyskinesias
Transgenic Models
D3R overexpression leads to enhanced rewarding effects of cocaine
Humanized DRD3 mice for drug testing
PD models with D3R manipulation show altered dyskinesia phenotypes
Research Directions
Biomarkers : D3R imaging ligands for PD progressionPersonalized medicine : DRD3 genotyping for treatment selectionDisease modification : D3R agonists as disease-modifying agentsCombination therapies : D3R-targeted approaches with other mechanisms
Background The study of Drd3 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
See Also
[Dopamine Receptors](/entities/dopamine)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Basal Ganglia](/brain-regions/basal-ganglia)
[Dyskinesia Treatments](/content/treatments)
[Neurotransmitter Systems](/mechanisms/neurotransmitter-systems)
D1 Receptors
D2 Receptors
[Nucleus Accumbens](/cell-types/nucleus-accumbens-shell-neurons)
[Levodopa-Induced Dyskinesias](/experiments/levodopa-induced-dyskinesia-mechanism)
External Links
[NCBI Gene: DRD3](https://www.ncbi.nlm.nih.gov/gene/1818)
[UniProt: DRD3](https://www.uniprot.org/uniprot/P35462)
[Human Protein Atlas: DRD3](https://www.proteinatlas.org/ENSG00000151577-DRD3)
[IUPHAR Database: D3 Receptor](https://www.guidetopharmacology.org/GRID/IUPHAR/D3.jsp)
References
[Unknown, - Human dopamine D3 receptor gene: structure and expression (n.d.)](PMID: 2154083 (https://pubmed.ncbi.nlm.nih.gov/2154083/))
[Unknown, - D3 receptor in the limbic system: localization and function (n.d.)](PMID: 8288280 (https://pubmed.ncbi.nlm.nih.gov/8288280/))
[Unknown, - Dopamine D3 receptor and Parkinson's disease (n.d.)](PMID: 10619475 (https://pubmed.ncbi.nlm.nih.gov/10619475/))
[Unknown, - Role of D3 receptors in levodopa-induced dyskinesias (n.d.)](PMID: 14598257 (https://pubmed.ncbi.nlm.nih.gov/14598257/))
[Unknown, - Therapeutic targeting of dopamine D3 receptor (n.d.)](PMID: 15723239 (https://pubmed.ncbi.nlm.nih.gov/15723239/))
[Unknown, - D3 receptor mechanisms in addiction (n.d.)](PMID: 19126755 (https://pubmed.ncbi.nlm.nih.gov/19126755/))
[Unknown, - Restless leg syndrome and dopamine receptors (n.d.)](PMID: 23651826 (https://pubmed.ncbi.nlm.nih.gov/23651826/))
[Unknown, - DRD3 polymorphisms in Parkinson's disease (n.d.)](PMID: 26786091 (https://pubmed.ncbi.nlm.nih.gov/26786091/))
Pathway Diagram The following diagram shows the key molecular relationships involving DRD3 Gene discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)
Show full description